Immunome, Inc. (IMNM) Free cash flow 2019–2025
Immunome, Inc. (IMNM) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$200.6MFY2025 · since FY2019: -$9.8M → -$200.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$200.6M | -70.1% |
| FY2024 | -$118.0M | -1304.5% |
| FY2023 | -$8.4M | +71.0% |
| FY2022 | -$28.9M | -58.1% |
| FY2021 | -$18.3M | -43.9% |
| FY2020 | -$12.7M | -29.4% |
| FY2019 | -$9.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMNM financial trends
IMNM RevenueIMNM Net incomeIMNM Net marginIMNM Gross profitIMNM Gross marginIMNM Operating incomeIMNM Operating marginIMNM Operating cash flowIMNM Capital expendituresIMNM Return on equityIMNM Stock buybacksIMNM Dividends paidIMNM Total assetsIMNM Total liabilitiesIMNM Shareholders’ equityIMNM overview →